url:https://finance.yahoo.com/m/e0b1b6c1-8342-358d-921b-c3e233096d9a/why-moderna-stock-plummeted.html
title:Why_Moderna_Stock_Plummeted_by_Almost_7_Today
A quarterly bottom line that was deep in the red sent Moderna (NASDAQ: MRNA) shareholders booking for the exits on Thursday. Its cost of sales should come in at around $5 billion, which includes what the biotech terms as a "proactive resizing of the company's manufacturing footprint" that is anticipated to total $1.6 billion across the third and fourth quarters alone.